Search Results 351-360 of 11028 for SC

  1. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

    About this study. The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in ...

  2. Alumni - Spine Surgery Fellowship (Minnesota) - Mayo Clinic College of Medicine & Science

    Alumni · Testimonial videos · Adan Omar, M.D. · Benjamin Streufert, M.D. · Sandra Hobson, M.D. · Jad Bou Monsef, M.D. · Alumni spotlight · Ilyas Aleem, M.D., M.Sc.

  3. Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma - Mayo Clinic

    ... SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma. Participation eligibility. Participant eligibility ...

  4. Curriculum - Magnetic Resonance Imaging (MRI) Program (Minnesota) - Mayo Clinic College of Medicine & Science

    He studied physics at the University of Dublin Trinity College, Ireland (B.Sc., M.Sc.), and earned a Ph.D. in MR physics at the University of Aberdeen, UK ...

  5. Publications - Hatem Amer, M.D. - Mayo Clinic

    ... SC, Kremers WK, Lerman LO. Association of kidney function and metabolic risk factors with density of glomeruli on renal biopsy samples from living donors ...

  6. A Study to Evaluate the Safety and Effectiveness of Gantenerumab in Participants With Early Alzheimer's Disease (AD) - Mayo Clinic

    Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will ...

  7. Stroke Core Measure - Mayo Clinic

    SC: Mayo Clinic Breadcrumb. About Mayo Clinic · Quality & Mayo Clinic · Quality measures. Sections Quality measures. Arizona · Florida · Minnesota · Event ...

  8. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

    ... SC dose at Week 2 [or one 80 mg SC dose at Baseline, followed by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]); OR; At ...

  9. In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls

    The purpose of this study is to evaluate the impact of the location of SQ Nivo administration, at the infusion center or in the home, on patient preference and ...

  10. Judy C. Boughey, M.D. - Doctors and Medical Staff - Mayo Clinic

    She completed her residency at the University of South Carolina and her breast surgery fellowship at the University of Texas, M.D. Anderson Cancer Center. In ...